- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02603081
Study to Evaluate SPI-1005 in Adults With Meniere's Disease
March 15, 2021 updated by: Sound Pharmaceuticals, Incorporated
Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease
This study will evaluate the safety and efficacy of three dose levels of SPI-1005 compared to placebo on vertigo, tinnitus and sensorineural hearing loss in 40 adults with Meniere's disease.
Study Overview
Detailed Description
Randomized, double-blind, placebo-controlled safety, pharmacokinetic, pharmacodynamic study of oral SPI-1005 in adults with Meniere's disease.
All subjects will undergo baseline audiometric testing and have their severity of sensorineural hearing loss, tinnitus and vertigo determined before the start of a 21-day course of treatment with SPI-1005 or placebo.
During treatment with SPI-1005, and 7 days and 28 days following the cessation of SPI-1005, subjects will have their hearing loss, tinnitus and vertigo assessed.
Additional testing including electrocochleography will be performed at baseline, at the end of SPI-1005 treatment, and 28 days after the SPI-1005 treatment has stopped.
Six outpatient visits will be performed over a 7-week period.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90057
- House Clinic
-
-
New York
-
New York, New York, United States, 10028
- New York Otology
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- MUSC
-
-
Washington
-
Seattle, Washington, United States, 98103
- Sound Pharmaceuticals, Inc.
-
Seattle, Washington, United States, 98104
- Northwest Ear
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of probable or definite Meniere's Disease by AAO-HNS 1995 criteria within 12 months of study enrollment;
- Voluntarily consent to participate in the study;
Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods:
- Sexual abstinence (inactivity) for 14 days prior to screening through study completion; or
- IUD in place for at least 3 months prior to study through study completion; or
- Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening through study completion; or
- Stable hormonal contraceptive for at least 3 months prior to study through study completion; or
- Surgical sterilization (vasectomy) of partner at least 6 months prior to study.
- Females of non-childbearing potential should be surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be at least 3 years since last menses.
Exclusion Criteria:
- Current use or within 90 days prior to study of ototoxic medications such as aminoglycoside antibiotics (gentamicin, tobramycin, amikacin, streptomycin); platinum-containing chemotherapies (cisplatin, carboplatin, oxaliplatin); or loop diuretic (furosemide);
- History of idiopathic sensorineural hearing loss, otosclerosis, or vestibular schwannoma;
- History of middle ear or inner ear surgery;
- Current conductive hearing loss or middle ear effusion;
- Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, or psychiatric disease;
- History of hypersensitivity or idiosyncratic reaction to compounds related to ebselen;
- Current use or within 30 days prior to study of drugs or substances known to be strong inhibitors or inducers of cytochrome P450 enzymes;
- Participation in another investigational drug or device study within 90 days prior to study enrollment;
- Female patients who are pregnant or breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
0 mg SPI-1005 bid po x 21d
|
Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx).
GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety.
Ebselen has strong anti-inflammatory characteristics.
Other Names:
|
Active Comparator: Low dose
200 mg SPI-1005 bid po x 21d
|
Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx).
GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety.
Ebselen has strong anti-inflammatory characteristics.
Other Names:
|
Active Comparator: Mid dose
400 mg SPI-1005 bid po x 21d
|
Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx).
GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety.
Ebselen has strong anti-inflammatory characteristics.
Other Names:
|
Active Comparator: High dose
600 mg SPI-1005 bid po x 21d
|
Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx).
GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety.
Ebselen has strong anti-inflammatory characteristics.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of SPI-1005 using histories, physical exams, and clinical measures.
Time Frame: 7 weeks
|
Incidence of of Treatment-Emergent Adverse Events
|
7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Ebselen levels of SPI-1005 before, during, and after 21 days of dosing
Time Frame: 7 weeks
|
Evaluation of potential accumulation of study drug
|
7 weeks
|
Plasma Selenium levels before, during, and after 21 days of dosing
Time Frame: 7 weeks
|
Evaluation of potential changes in plasma selenium levels
|
7 weeks
|
Impact on Sensorineural Hearing Loss
Time Frame: 7 weeks
|
Pure Tone Audiometry
|
7 weeks
|
Impact on Speech Discrimination
Time Frame: 7 weeks
|
Words in Noise Test
|
7 weeks
|
Impact on Tinnitus
Time Frame: 7 weeks
|
Questionnaire
|
7 weeks
|
Impact on Vertigo
Time Frame: 7 weeks
|
Questionnaire
|
7 weeks
|
Pharmacodynamic response
Time Frame: 7 weeks
|
Electrocochleography
|
7 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Jonathan Kil, MD, Sound Pharmaceuticals
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Garland M, Hryckowian AJ, Tholen M, Bender KO, Van Treuren WW, Loscher S, Sonnenburg JL, Bogyo M. The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI. Cell Rep Med. 2020 Apr 21;1(1):100005. doi: 10.1016/j.xcrm.2020.100005.
- Kil J, Harruff EE, Longenecker RJ. Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hear Res. 2022 Jan;413:108209. doi: 10.1016/j.heares.2021.108209. Epub 2021 Feb 19.
- Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007 Apr;226(1-2):44-51. doi: 10.1016/j.heares.2006.08.006. Epub 2006 Oct 6.
- Lynch E, Kil J. Development of ebselen, a glutathione peroxidase mimic, for the prevention and treatment of noise-induced hearing loss. Semin Hear 2009; 30(1):47-55.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Actual)
August 1, 2017
Study Completion (Actual)
August 1, 2017
Study Registration Dates
First Submitted
November 2, 2015
First Submitted That Met QC Criteria
November 10, 2015
First Posted (Estimate)
November 11, 2015
Study Record Updates
Last Update Posted (Actual)
March 18, 2021
Last Update Submitted That Met QC Criteria
March 15, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Otorhinolaryngologic Diseases
- Labyrinth Diseases
- Ear Diseases
- Endolymphatic Hydrops
- Meniere Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gastrointestinal Agents
- Neuroprotective Agents
- Protective Agents
- Anti-Ulcer Agents
- Antioxidants
- Ebselen
Other Study ID Numbers
- SPI-1005-151
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meniere's Disease
-
University Hospital, GrenobleNot yet recruitingInner Ear ; Meniere's Disease; Imaging
-
Norfolk and Norwich University Hospitals NHS Foundation...University of East Anglia; Ménière's SocietyCompleted
-
Medical University of South CarolinaAmerican Hearing Research Foundation; Cures within Reach FoundationCompletedMeniere DiseaseUnited States
-
Otonomy, Inc.Terminated
-
Beijing Tongren HospitalCompleted
-
Otonomy, Inc.Terminated
-
Alvogen KoreaCompleted
-
Ludwig-Maximilians - University of MunichCompletedMénière's DiseaseGermany
-
University Hospital, BordeauxCompleted
-
University of California, San DiegoAmerican Society of Head and Neck RadiologyCompletedMeniere's DiseaseUnited States
Clinical Trials on SPI-1005
-
Sound Pharmaceuticals, IncorporatedMedical University of South Carolina; Cystic Fibrosis FoundationEnrolling by invitation
-
Sound Pharmaceuticals, IncorporatedUniversity of FloridaCompletedTemporary Auditory Threshold ShiftUnited States
-
Sound Pharmaceuticals, IncorporatedVA Puget Sound Health Care SystemUnknownHead and Neck Cancer | Lung Cancer | Hearing Loss | Ototoxicity | Tinnitus | NeuropathyUnited States
-
Sound Pharmaceuticals, IncorporatedCompleted
-
Sound Pharmaceuticals, IncorporatedUnknownNoise Induced Hearing LossUnited States
-
Veralox TherapeuticsCompletedSafety and Tolerability in Healthy VolunteersUnited States
-
University of Firenze and Siena, Napoli, ItalyCompletedThick Gingival Margin to Tooth RestorationItaly
-
Staidson Biopharma Inc.Completed
-
University of ChicagoAbbVieCompleted
-
Hunazine Biotech S.L.Recruiting